Capecitabine + temozolomide (CAPTEM)
CAPTEM (capecitabine plus temozolomide) is an all-oral chemotherapy pair that shrinks pancreatic neuroendocrine tumours in about a third of patients.
ECOG-ACRIN E2211 (2018-2023): PFS 22.7 vs 14.4 months and higher response rate for CAPTEM versus temozolomide alone in pancreatic NETs; OS not significantly different at final analysis. Used when tumour shrinkage is needed (bulky or symptomatic disease) and in grade 3 NETs. MGMT deficiency may predict response.
- Route
- Oral
- Schedule
- Capecitabine 750 mg/m² twice daily days 1-14, temozolomide 200 mg/m² days 10-14, every 28 days
- Monitoring
- Blood counts, hand-foot syndrome
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia (grade 3-4) | — | 13% |
| Thrombocytopenia (grade 3-4) | — | 15% |
| Fatigue | 50% | — |
E2211. Events listed without rates were not read from a primary source; see the label. Blank cells mean the figure was not sourced, not that it is zero.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Capecitabine + temozolomide" OR ABSTRACT:"Capecitabine + temozolomide" OR TITLE:"CAPTEM" OR ABSTRACT:"CAPTEM") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Capecitabine + temozolomide (CAPTEM), not a curated reading list.